This paper is in the following e-collection/theme issue:

Clinical Information and Decision Making (1915) mHealth in a Clinical Setting (743) Decision Support for Health Professionals (1539) Dementia and Cognitive Decline (696) Digital Health Reviews (1724) New Methods (1134) Research Instruments, Questionnaires, and Tools (738)

Published on in Vol 27 (2025)

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/68454, first published .
Clinical Benefits and Risks of Antiamyloid Antibodies in Sporadic Alzheimer Disease: Systematic Review and Network Meta-Analysis With a Web Application

Clinical Benefits and Risks of Antiamyloid Antibodies in Sporadic Alzheimer Disease: Systematic Review and Network Meta-Analysis With a Web Application

Clinical Benefits and Risks of Antiamyloid Antibodies in Sporadic Alzheimer Disease: Systematic Review and Network Meta-Analysis With a Web Application

Authors of this article:

Danko Jeremic1 Author Orcid Image ;   Juan D Navarro-Lopez1 Author Orcid Image ;   Lydia Jimenez-Diaz1 Author Orcid Image
Article Authors Cited by (5) Tweetations (1) Metrics

Journals

  1. Xing H, Yue S, Qin R, Du X, Wu Y, Zhangsun D, Luo S. Recent Advances in Drug Development for Alzheimer’s Disease: A Comprehensive Review. International Journal of Molecular Sciences 2025;26(8):3905 View
  2. Sulatsky M, Stepanenko O, Stepanenko O, Sulatskaya A. Solving the Amyloid Paradox: Unveiling the Complex Pathogenicity of Amyloid Fibrils. Aggregate 2025;6(7) View
  3. Mulero-Franco J, Jimenez-Herrera R, Contreras A, Djebari S, Jiménez-Díaz L, Navarro-López J. VU0810464, a selective GIRK channel activator, improves hippocampal-dependent synaptic plasticity and memory disrupted by amyloid-β oligomers. Biomedicine & Pharmacotherapy 2025;189:118247 View
  4. Almohmadi N, Al-Kuraishy H, Albuhadily A, Al-Gareeb A, Abdelaziz A, Alexiou A, Papadakis M, El-Saber Batiha G. Alzheimer disease: Amyloid peptide controversies and challenges of anti-Aβ immunotherapy. The Journal of Pharmacology and Experimental Therapeutics 2025;392(8):103639 View
  5. Elamin S, Al Shibli A, Shaito A, Al-Maadhadi M, Zolezzi M, Pedersen S. Anti-amyloid monoclonal antibody therapies in Alzheimer’s disease – a scoping review. Neuroscience 2025;589:50 View